Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2020; 12(01): 38-43
DOI: 10.1055/s-0040-1714933
Original Article

Evaluation of Angiogenesis in Multiple Myeloma by VEGF Immunoexpression and Microvessel Density

Anshu Palta
1   Department of Pathology, Government Medical College and Hospital, Chandigarh, India
,
Manveen Kaur
1   Department of Pathology, Government Medical College and Hospital, Chandigarh, India
,
Anita Tahlan
1   Department of Pathology, Government Medical College and Hospital, Chandigarh, India
,
Kislay Dimri
2   Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India
› Author Affiliations Sources of support None.
› Further Information
   Permissions and Reprints

Abstract

Background Multiple myeloma (MM) is a plasma cell disorder characterized by monoclonal proliferation of plasma cells in bone marrow. Plasmablastic MM is a morphologic subset of MM, containing ≥2% plasmablasts of all plasma cells.

Methods The study included 30 consecutively diagnosed patients of MM (6 plasmablastic, 24 nonplasmablastic) over a span of 2 years. Angiogenesis in MM was assessed by analysis of vascular endothelial growth factor (VEGF) immunoexpression by plasma cells and microvessel density (MVD) using anti-CD34 antibody. CD34 and VEGF immunohistochemical staining was performed in all the 30 cases. Angiogenesis was studied in relation to plasmablastic morphology and clinical profile to determine if any correlation exists between these.

Results The mean VEGF expression of 80.83 ± 7.36 in plasmablastic myeloma cases was significantly higher compared with a mean VEGF of 53.54 ±17.09 in nonplasmablastic cases. Most of the cases (66.6%) of plasmablastic myeloma exhibited strong (3+) VEGF expression. The difference in mean VEGF expression between plasmablastic and nonplasmablastic cases was found to be statistically significant (p = 0.001). The mean MVD in plasmablastic cases was 44.8 ± 3.69, while in the nonplasmablastic category, the mean MVD was 23.7 ± 5.14, difference being statistically significant (p < 0.05). Also, a positive correlation was found between VEGF expression and MVD.

Conclusion A moderate/strong VEGF intensity and higher MVD were found in cases of plasmablastic MM, suggesting that a more aggressive histological disease may be associated with increased production of VEGF. This finding might be helpful to identify a subset of patients with adverse prognosis and to provide antiangiogenic therapy to improve their survival. However, studies comprising larger number of patients are required to bring out a statistical significance to further substantiate these findings.

Keywords

multiple myeloma - plasmablastic - angiogenesis - microvessel density - vascular endothelial growth factor


Publication History

Article published online:
24 July 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 McKenna RW, Kyle RA, Keuhl WM, Harris NL, Coupland RW, Fend F. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri Sa, Stein H. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC; 2017: 243-250
    Google Scholar
  • 2 Greipp PR, Raymond NM, Kyle RA, O’Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65 (02) 305-310
    CrossrefPubMedGoogle Scholar
  • 3 Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002; 55 (07) 530-534
    CrossrefPubMedGoogle Scholar
  • 4 Rajkumar SV, Mesa RA, Fonseca R. et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8 (07) 2210-2216
    PubMedGoogle Scholar
  • 5 Podar K, Tai YT, Davies FE. et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98 (02) 428-435
    CrossrefPubMedGoogle Scholar
  • 6 Giuliani N, Storti P, Bolzoni M, Palma BD, Bonomini S. Angiogenesis and multiple myeloma. Cancer Microenviron 2011; 4 (03) 325-337
    CrossrefPubMedGoogle Scholar
  • 7 Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59 (03) 728-733
    PubMedGoogle Scholar
  • 8 Kumar S, Fonseca R, Dispenzieri A. et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003; 101 (05) 1715-1717
    CrossrefPubMedGoogle Scholar
  • 9 Bhatti SS, Kumar L, Dinda AK, Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am J Hematol 2006; 81 (09) 649-656
    CrossrefPubMedGoogle Scholar
  • 10 Greipp PR, Leong T, Bennett JM. et al. Plasmablastic morphology–an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91 (07) 2501-2507
    CrossrefPubMedGoogle Scholar
  • 11 Jakob C, Sterz J, Zavrski I. et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006; 42 (11) 1581-1590
    CrossrefPubMedGoogle Scholar
  • 12 Himani B, Meera S, Abhimanyu S, Usha R. Ki-67 immunostaining and its correlation with microvessel density in patients with multiple myeloma. Asian Pac J Cancer Prev 2016; 17 (05) 2559-2564
    PubMedGoogle Scholar
  • 13 Lee N, Lee H, Moon SY. et al. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Ann Lab Med 2015; 35 (06) 563-569
    CrossrefPubMedGoogle Scholar
  • 14 Ria R, Berardi S, Reale A, Luisi AD, Catacchio I. Multiple myeloma: the role of angiogenesis in disease progression. J Bone Marrow Res 2013; 1: 117-119
    Google Scholar
  • 15 Subramanian R, Basu D, Dutta TK. Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer 2009; 46 (01) 40-45
    CrossrefPubMedGoogle Scholar
  • 16 Singhal N, Singh T, Singh ZN, Shome DK, Gaiha M. Histomorphology of multiple myeloma on bone marrow biopsy. Indian J Pathol Microbiol 2004; 47 (03) 359-363
    PubMedGoogle Scholar
  • 17 Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv 2017; 1 (04) 282-287
    CrossrefPubMedGoogle Scholar
  • 18 Ribas C, Colleoni GW, Almeida MS, Aguiar KC, Silva MR, Bordin JO. Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression. Braz J Med Biol Res 2005; 38 (11) 1609-1613
    CrossrefPubMedGoogle Scholar